Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Apr 14, 2023 4:12pm
68 Views
Post# 35395972

RE:RE:RE:RE:RE:RE:RE:RE:AACR - late breaking absracts text posted by noon today

RE:RE:RE:RE:RE:RE:RE:RE:AACR - late breaking absracts text posted by noon todayI am told the full abstracts will be released on Tuesday morning. 

Wino115 wrote: I posted a Laymans interpretation of this study yesterday.  You can find that post under my name somewhere.  It interprets the abstract piece by piece, but cautions we need to see numbers and see the degree to which they are both turning a cold tumor hot, which is a potentially significant scientific development as far as immunotherapy in cancer goes, and the degree to which the "delta" in the combo on various readings like survival, tumor growth, etc.. is decently significant, knowing that in cancer studies just adding 10% to reponse rates or 2 months to survival is considered a win (unfortunately). 


<< Previous
Bullboard Posts
Next >>